10,894 Shares in Neon Therapeutics Inc (NTGN) Acquired by Highland Capital Management LP

Highland Capital Management LP acquired a new position in shares of Neon Therapeutics Inc (NASDAQ:NTGN) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 10,894 shares of the company’s stock, valued at approximately $137,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Point72 Hong Kong Ltd purchased a new stake in shares of Neon Therapeutics during the 2nd quarter worth $105,000. Maso Capital Partners Ltd purchased a new stake in shares of Neon Therapeutics during the 2nd quarter worth $441,000. Dean Capital Investments Management LLC purchased a new stake in shares of Neon Therapeutics during the 2nd quarter worth $504,000. United Services Automobile Association purchased a new stake in shares of Neon Therapeutics during the 2nd quarter worth $607,000. Finally, DAFNA Capital Management LLC purchased a new stake in shares of Neon Therapeutics during the 2nd quarter worth $630,000. Hedge funds and other institutional investors own 65.75% of the company’s stock.

A number of research firms have commented on NTGN. LADENBURG THALM/SH SH began coverage on Neon Therapeutics in a research note on Monday, October 1st. They issued a “buy” rating and a $20.00 price target for the company. Cann reiterated a “buy” rating and issued a $20.00 price target on shares of Neon Therapeutics in a research note on Tuesday, August 7th. Oppenheimer began coverage on Neon Therapeutics in a research note on Monday, July 23rd. They issued a “$11.74” rating and a $20.00 price target for the company. Morgan Stanley began coverage on Neon Therapeutics in a research note on Monday, July 23rd. They issued an “overweight” rating and a $23.00 price target for the company. Finally, Bank of America began coverage on Neon Therapeutics in a research note on Monday, July 23rd. They issued a “buy” rating and a $18.00 price target for the company. Four analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $20.20.

Shares of NASDAQ:NTGN traded up $0.26 during trading on Friday, hitting $10.91. The stock had a trading volume of 126,337 shares, compared to its average volume of 128,166. Neon Therapeutics Inc has a 12-month low of $6.17 and a 12-month high of $16.23.

Neon Therapeutics (NASDAQ:NTGN) last announced its quarterly earnings data on Monday, August 6th. The company reported ($7.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($7.04). As a group, equities analysts predict that Neon Therapeutics Inc will post -5.5 earnings per share for the current fiscal year.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Further Reading: Growth Stocks, What They Are, What They Are Not

Institutional Ownership by Quarter for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply